While this happened, Evercore ISI downgraded its Cabaletta Bio Inc [CABA] rating to an In-line from a an Outperform in a research note published on December 20, 2024; the price target was decreased to $6 from $15. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who decreased its forecast for the stock in mid December from “an Overweight” to “an Equal weight”. UBS began covering CABA with “Buy” recommendation on October 10, 2024. Jefferies started covering the stock on February 05, 2024. It rated CABA as “a Buy”.
Price Performance Review of CABA
On Tuesday, Cabaletta Bio Inc [NASDAQ:CABA] saw its stock fall -10.16% to $1.15. Over the last five days, the stock has lost -10.16%. Cabaletta Bio Inc shares have fallen nearly -49.34% since the year began. Nevertheless, the stocks have fallen -90.87% over the past one year. While a 52-week high of $13.50 was reached on 02/18/25, a 52-week low of $0.99 was recorded on 04/07/25. SMA at 50 days reached $1.4771, while 200 days put it at $3.2656.
Levels Of Support And Resistance For CABA Stock
The 24-hour chart illustrates a support level at 1.0900, which if violated will result in even more drops to 1.0300. On the upside, there is a resistance level at 1.2600. A further resistance level may holdings at 1.3700. The Relative Strength Index (RSI) on the 14-day chart is 40.57, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0110, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.29%. Stochastics %K at 56.19% indicates the stock is a holding.
The most recent change occurred on November 29, 2023 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating along with a $38 price target.
